Health Alert:

See the latest Coronavirus Information including testing sites, visitation restrictions, appointments and scheduling, and more.



Our research group focuses on the development and clinical translation of radiopharmaceutical therapeutics for applications in oncology.

We are currently evaluating two astatinated alpha-emitting radiotherapeutics including [211At]MABG (norepinephrine substrate) and [211At]MM4 (PARP inhibitor) for the treatment of neuroblastoma. The development of [211At]MABG is highly collaborative between the Pryma and Maris lab (CHOP) with high potential for clinical translation in the near future. Dan Pryma’s clinical work led to the [131I]MIBG FDA approval for the treatment of pheochromocytoma. The Makvandi lab studies the relative biological effectiveness of alpha-particles and auger electrons using radiopharmaceuticals which target the DNA within the nucleus in engineered cell systems. The Carlin lab is working on developing companion diagnostics for radiotherapeutics and antibody drug conjugates.



Faculty And Staff

Daniel Pryma, MD

Daniel Pryma, MD

  • Division Chief, Nuclear Medicine and Clinical Molecular Imaging
  • Associate Professor of Radiology at the Hospital of the University of Pennsylvania
  • Associate Professor of Radiation Oncology

View Full Profile

Head shot of Mehran Makvandi

Mehran Makvandi, PharmD, RPh, BCNP

Assistant Professor of Radiology at the Hospital of the University of Pennsylvania

View Full Profile

Sean D. Carlin, PhD

Sean D. Carlin, PhD

Research Associate Professor of Radiology

View Full Profile

Head shot silhouette

Adam Mansfield


Recent Publications

1. Pryma, et al. Efficacy and Safety of High-Specific-Activity 131I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma. J Nucl Med. 2019 May;60(5):623-630. doi: 10.2967/jnumed.118.217463. Epub 2018 Oct 5.

2. Reilly SW, Makvandi M, Xu K, Mach RH. Rapid Cu-Catalyzed [211At]Astatination and [125I]Iodination of Boronic Esters at Room Temperature. Org Lett. 2018 Apr 6;20(7):1752-1755. doi: 10.1021/acs.orglett.8b00232. Epub 2018 Mar 21.

3. McKnight BN, Kuda-Wedagedara ANW, Sevak KK, Abdel-Atti D, Wiesend WN, Ku A, Selvakumar D, Carlin SD, Lewis JS, Viola-Villegas NT. Imaging EGFR and HER3 through 89Zr-labeled MEHD7945A (Duligotuzumab). Sci Rep. 2018 Jun 13;8(1):9043. doi: 10.1038/s41598-018-27454-6.

Contact Us

Daniel Pryma, MD

Sandra Carney

Share This Page: